Literature DB >> 3706242

The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia.

J A Wolff, S Kulovich, A L Yu, C N Qiao, W L Nyhan.   

Abstract

Patients with nonketotic hyperglycinemia generally have intractable seizures that are poorly responsive to anticonvulsant medication. No effective treatment has been consistently reported. In three patients with nonketotic hyperglycinemia, the oral administration of sodium benzoate in dosages designed to lower the cerebrospinal fluid concentration of glycine was followed by an abrupt change from frequent major seizures before treatment to no seizures, or only occasional minor ones, after treatment. This attenuation of seizures was associated with a decrease in the concentrations of glycine in both plasma and cerebrospinal fluid. There was no evident change in psychomotor development.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3706242     DOI: 10.1001/archpedi.1986.02140200106038

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  13 in total

1.  Tryptophan therapy for non-ketotic hyperglycinaemia.

Authors:  F Inoue; S Matsuo; H Yoshioka; Y Takeuchi; H Yamanaka; N Kodo; A Kinugasa; T Sawada
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Benzoate treatment and the glycine index in nonketotic hyperglycinaemia.

Authors:  J L K Van Hove; K Vande Kerckhove; J B Hennermann; V Mahieu; P Declercq; S Mertens; M De Becker; P S Kishnani; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Prediction of long-term outcome in glycine encephalopathy: a clinical survey.

Authors:  Julia B Hennermann; Jeanne-Marie Berger; Ulrike Grieben; Gunter Scharer; Johan L K Van Hove
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

Review 4.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

5.  [Clinical and molecular genetic characteristics of nonketotic hyperglycinemia].

Authors:  Hai-Feng Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

6.  Effect of sodium benzoate in the treatment of atypical nonketotic hyperglycinaemia.

Authors:  J M Neuberger; S Schweitzer; M O Rolland; R Burghard
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

7.  Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship.

Authors:  G L Arnold; M L Griebel; J L Valentine; D M Koroma; G L Kearns
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

8.  Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia.

Authors:  B A Barshop; J Breuer; J Holm; J Leslie; W L Nyhan
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

9.  Ketamine and strychnine treatment of an infant with nonketotic hyperglycinaemia.

Authors:  H Tegtmeyer-Metzdorf; B Roth; M Günther; M Theisohn; U Heinemann; H A Adams; G Sticht
Journal:  Eur J Pediatr       Date:  1995-08       Impact factor: 3.183

10.  Genotypic and phenotypic features in Turkish patients with classic nonketotic hyperglycinemia.

Authors:  Harun Bayrak; Yılmaz Yıldız; Asburçe Olgaç; Çiğdem Seher Kasapkara; Aynur Küçükcongar; Ayşegül Zenciroğlu; Deniz Yüksel; Serdar Ceylaner; Mustafa Kılıç
Journal:  Metab Brain Dis       Date:  2021-04-01       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.